Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Daunorubicin (Zentiva) 20mg powder for IV injection
Section 19A approved medicine
(Approval lapsed) Daunorubicin (Zentiva) 20mg powder for IV injection
Section 19A approval holder
Link Medical Products Pty Ltd ABN: 73 010 971 516
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
Pfizer (Australia) DAUNORUBICIN (as hydrochloride) 20mg/10mL injection vial
Indication(s)
- Acute lymphocytic (lymphoblastic) leukaemia: Daunorubicin is usually reserved for use in cases shown to be resistant to other drugs. However, combined treatment with daunorubicin, vincristine and a steroid has been used in the early stages of this disease.
- Acute myeloblastic leukaemia: Daunorubicin has been used in all stages, alone or in combination with other cytotoxic agents (e.g., cytarabine).